WallStreetZenWallStreetZen

NASDAQ: CASI
Casi Pharmaceuticals Inc Stock

$3.24-0.22 (-6.36%)
Updated May 23, 2024
CASI Price
$3.24
Fair Value Price
N/A
Market Cap
$43.35M
52 Week Low
$1.85
52 Week High
$8.48
P/E
-1.6x
P/B
1.79x
P/S
2.82x
PEG
N/A
Dividend Yield
N/A
Revenue
$33.88M
Earnings
-$26.94M
Gross Margin
59.2%
Operating Margin
-79.75%
Profit Margin
-79.6%
Debt to Equity
2.12
Operating Cash Flow
-$20M
Beta
0.92
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

CASI Overview

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome. Its product pipeline also comprises CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; and Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors. The company has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.

Zen Score

Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CASI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CASI is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CASI is good value based on its book value relative to its share price (1.79x), compared to the US Biotechnology industry average (6.06x)
P/B vs Industry Valuation
CASI is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CASI due diligence checks available for Premium users.

Be the first to know about important CASI news, forecast changes, insider trades & much more!

CASI News

Valuation

CASI price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-1.6x
Industry
11.17x
Market
31.54x

CASI price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.79x
Industry
6.06x
CASI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

CASI's financial health

Profit margin

Revenue
$6.9M
Net Income
-$6.1M
Profit Margin
-88.4%
CASI's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
CASI's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$75.3M
Liabilities
$51.1M
Debt to equity
2.12
CASI's short-term assets ($59.34M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CASI's short-term assets ($59.34M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CASI's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CASI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
N/A
Investing
N/A
Financing
N/A
CASI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

CASI vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
CASI$43.35M-6.36%-1.60x1.79x
BLRX$44.04M-2.42%-10.08x3.33x
GANX$44.23M+0.82%-1.63x5.12x
OCUP$44.33M-3.39%-3.56x0.96x
IMRX$42.11M-8.39%-0.76x0.53x

Casi Pharmaceuticals Stock FAQ

What is Casi Pharmaceuticals's quote symbol?

(NASDAQ: CASI) Casi Pharmaceuticals trades on the NASDAQ under the ticker symbol CASI. Casi Pharmaceuticals stock quotes can also be displayed as NASDAQ: CASI.

If you're new to stock investing, here's how to buy Casi Pharmaceuticals stock.

What is the 52 week high and low for Casi Pharmaceuticals (NASDAQ: CASI)?

(NASDAQ: CASI) Casi Pharmaceuticals's 52-week high was $8.48, and its 52-week low was $1.85. It is currently -61.79% from its 52-week high and 75.14% from its 52-week low.

How much is Casi Pharmaceuticals stock worth today?

(NASDAQ: CASI) Casi Pharmaceuticals currently has 13,378,175 outstanding shares. With Casi Pharmaceuticals stock trading at $3.24 per share, the total value of Casi Pharmaceuticals stock (market capitalization) is $43.35M.

Casi Pharmaceuticals stock was originally listed at a price of $1,244.10 in Dec 31, 1997. If you had invested in Casi Pharmaceuticals stock at $1,244.10, your return over the last 26 years would have been -99.74%, for an annualized return of -20.46% (not including any dividends or dividend reinvestments).

How much is Casi Pharmaceuticals's stock price per share?

(NASDAQ: CASI) Casi Pharmaceuticals stock price per share is $3.24 today (as of May 23, 2024).

What is Casi Pharmaceuticals's Market Cap?

(NASDAQ: CASI) Casi Pharmaceuticals's market cap is $43.35M, as of May 24, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Casi Pharmaceuticals's market cap is calculated by multiplying CASI's current stock price of $3.24 by CASI's total outstanding shares of 13,378,175.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.